

Declaration of Interests Register

Technology Appraisal Committee A

Publication Date: 28/04/2021

Topic: Olaparib in combination with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy with bevacizumab [ID1652]

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Professor Iain McNeish	Clinical Expert	Direct financial	Has sat on advisory boards for AstraZeneca, GSK/Tesaro and Clovis Oncology, the companies that manufacture the three PARP inhibitors used in the treatment of ovarian cancer. He also declared an indirect professional financial interest as his institution receives grant income from AstraZeneca.		September 2020		Interests declared and participated in part 1 of the meeting. Agreed by Chair Dr Jane Adam
Dr Susana Banerjee	Clinical Expert	Direct financial	Has received honoraria for speaking engagements and advisory boards from AstraZeneca, GSK/Tesaro, Clovis Oncology and other possible comparator companies. She also declared an indirect professional financial interest as her institution receives funding for		September 2020		Interests declared and participated in part 1 of the meeting. Agreed by Chair Dr Jane Adam

			research from AstraZeneca and GSK/Tesaro.				
Ms Rachel Downing	Patient Expert	Indirect professional financial	She is employed by Target Ovarian Cancer who receive grants from a number of pharmaceutical companies including AstraZeneca.		September 2020		Interests declared and participated in part 1 of the meeting. Agreed by Chair Dr Jane Adam
Alice Turner	TAC A Committee Member	Indirect financial	Her employer has received grants from AstraZeneca in an unrelated disease area.		September 2020		Interests declared and participated in part 1 of the meeting. Agreed by Chair Dr Jane Adam